Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 3, 2005, Pages 283-288

  Cressey, Tim R ^a,b,g   Jourdain, Gonzague ^a,b   Lallemant, Marc J ^b   Kunkeaw, Suparat ^b   Jackson, J Brooks ^c   Musoke, Philippa ^d   Capparelli, Edmund ^e   Mirochnick, Mark ^f  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Institute of research for development Thailand   (Thailand)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Prasing Post   (Thailand)

Author keywords

Nevirapine; Pharmacokinetics; Prevention mother to child HIV transmission

Indexed keywords

NEVIRAPINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SIMULATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LABOR; MAJOR CLINICAL STUDY; MOTHER FETUS RELATIONSHIP; MULTICENTER STUDY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROPHYLAXIS; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; THAILAND; ZIDOVUDINE;

EID: 14744282818     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002;288:189-198.
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
3. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
4. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003; 187:725-735.
5. Cressey TR, Kunkeaw S, Ruttana-Aroongorn NP, et al. Duration of nevirapine (NVP) postpartum exposure in women who received single dose NVP during labor in addition to standard zidovudine (ZDV) prophylaxis for the prevention of mother-to-child transmission of HIV-1 in Thailand. Presented at: XV International AIDS Conference; 2004; Bangkok.
6. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68:1660-1666.
7. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951-1957.
8. Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis. 2002;186:181-188.
9. Viramune (nevirapine) tablets, oral suspension, package insert labeling, revision 9. Ingelheim, Germany: Boehringer-Ingelheim Pharmaceuticals; 1998.
10. European Agency for the Evaluation of Medicinal Product. European Public Assessment Report (EPAR). February 5, 1998. Revision 3, April 16, 1999. CPMP/1096/97.
11. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis. 1998;178:368-374.
12. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13:479-486.
13. Aarnoutse RE, Droste JA, van Oosterhout JJ, et al. Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers. Br J Clin Pharmacol. 2003;55:115-125.
14. Holland DT, DiFrancesco R, Stone J, et al. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004;48:824-831.
15. Asqualab. International QC program for TDM in HIV infection. Nice, France: Hopital Pasteur, CHU NICE, Laboratoire de pharmacologie; 2000.
16. Beal SL, Sheiner LB, Boeckmann AJ. NONMEM Users Guide. San Francisco: University of California, San Francisco: NONMEM Project Group; 1994.
17. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20:511-528.
18. Muro E, Droste J, Hofstede HT, et al. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose NVP: implications for intervention studies. Presented at: 11th CROI; 2004; San Francisco.
19. Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine: pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet. 2000;39:281-293.
20. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54: 1271-1294.
21. McIntyre J, Martnson N. 1413 IftT. Addition of short course Combivir (CBV) to single dose Viramune (sdNVP) for prevention of mother-to-child transmission (MTCT) of HIV-1 can significantly decrease the subsequent development of maternal NNRTI-resistant virus. Presented at: XV International AIDS Conference; 2004; Bangkok.
22. Mackie NE, Fidler S, Tamm N, et al. Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Med. 2004;5:180-184.